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Abstract. Recently, increasing number of infectious diseases has swept the world. The 
outbreak of a contagious disease not only affects the health and lives of people but also 
causes economic growth to stagnate. Business in the biotechnology industry is closely 
related to infectious diseases but what exactly is the information value of the outbreak 
of infectious disease on biotechnology? This study investigates how such outbreaks can 
affect the performance of biotechnology stocks. In the past 10 years, major statutory 
infectious diseases in Taiwan have included ENTEROVIRUS 71, DENGUE FEVER, 
SARS and H1N1. The empirical results indicate that there is a significant abnormal return 
on company shares in Taiwan’s biotechnology industry because of statutory infectious 
epidemics. The relationship between the financial ratios of biotechnology companies and 
abnormal returns was analyzed as part of this research. The results show that the influence 
on R&D ratios, current ratios and assets are significant. Empirical findings reveal that the 
investors rationally measure operating conditions of the biotechnology companies during 
outbreaks of major infectious disease and adjust portfolio allocation accordingly.
Keywords: biotechnology industry, infectious diseases, investor’s perspective, abnormal 
returns, stock performance, risk factor, market model.
Reference to this paper should be made as follows: Wang, Y.-H.; Yang, F.-J.; Chen, L.-J. 
2013. An investor’s perspective on infectious diseases and their influence on market be-
havior, Journal of Business Economics and Management 14(Supplement 1): S112–S127.
JEL Classification: G14.
Introduction
Biotechnology in the 21st century is a very active field. Many countries, including 
Taiwan, invest heavily in biotechnology industry. Biotechnology industry is a high-tech 
industry and its development requires the input of a lot of capital and technology (Hall, 
Bagchi-Sen 2002). As early as the 1990s, the Taiwanese government had already started 
to formulate industrial development strategies; as a result of incentives provided, many 
biotechnology companies were established. Because the establishment of new compa-
nies is very important to a country’s economic health and capital markets, Taiwan’s gov-
ernment hopes that these newly established biotech companies will promote economic 
competiveness (Hsu et al. 2005; Strandskov 2006).
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Taiwan’s biotechnology industry can be divided into three major categories: pharmaceu-
ticals, medical products, and other medical-related areas such as retail medical supplies. 
The operating revenue of the biotechnology industry amounted to NT 2,105 million in 
2009; the greatest proportion was in medical products, where revenues reached NT 825 
million. The pharmaceutical category accounted for NT 700 million. Aside from eco-
nomic development, the biotechnology industry benefits of all mankind. In recent years, 
an increasing number of infectious life-threatening diseases swept the world. The goal 
of developments in biotechnology is to treat or prevent diseases, and reduce the social 
impact of infectious diseases. Pandemic infectious diseases can negatively impact the 
national economy and to neglect them may cause heavy financial losses (Mayer 2000; 
Zhang et al. 2009).
The SARS epidemic struck Asian countries in 2003 causing a significant drop in tour-
ism in the region. Because of different levels of damage, the tourism industry in Asian 
countries was affected to different degrees by SARS (Page et al. 2006; Kuo et al. 2008). 
China was affected most; not only was tourism impacted but also retail sales, restau-
rants, hotels and the air transport industry (Keogh-Brown, Richard 2008). The SARS 
epidemic also affected the stock performance of many industries producing significantly 
negative cumulative abnormal returns in the chemicals, construction, department stores, 
food, hotels, textiles and automobile sectors in Taiwan (Chen et al. 2005; Chen et al. 
2007; Chen 2011).
Whereas infectious diseases affect the stock performance of many industries do they 
also affect the stock performance of the biotechnology industry? As a disease spreads, 
demand for medicines, vaccines and related medical products tend to increase. As a 
result, major related R&D activities in biotechnological research within Asia may ben-
efit (Wang et al. 2010). The biotechnology industry is committed to developing new 
products and producing economic rewards for the long term (Niosi 2003). Investors and 
shareholders are not myopic in their analysis of the true value of an emerging company 
(McMillan, Thomas 2005; Namara, Baden-Fuller 2007; Wang 2009; Ramchander et al. 
2012). The outbreak of an infectious disease may be long or short term, but overall stock 
performance within the biotechnology industry is as yet unknown.
Specifically, the purpose of this paper is to investigate how the outbreak of infectious 
diseases affects stock performance within the biotechnology industry. According to the 
literature, there have been significant abnormal returns within Taiwan’s biotechnology 
industry because of infectious epidemics (Yang et al. 2010). Along with the findings 
described by Yang et al. (2010), we have added more observations and used financial 
ratios to explain these abnormal returns. The rest of this paper is organized as follows. 
Section 1 describes data sources and the methodology. Section 2 discusses the empirical 
results and the last section concludes this paper.
1. Methodology 
1.1. Data source
The data sources used for this study are: the prospectuses of Taiwanese listed companies 
on TSEC and OTC, the TEJ database and the UDN databases. ENTEROVIRUS 71, 
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DENGUE FEVER, SARS and H1N1 were four specific infectious disease outbreaks in 
Taiwan within the past fifteen years. There are 75 observations belonging to 38 biotech 
companies. 
The biotechnology industry is divided into three major categories: pharmaceuticals, 
medical products, and other medical-related products. There are 36 observations be-
longing to the pharmaceutical category, 29 observations belonging to the medical prod-
uct category and 10 observations belonging to other medical-related categories, which 
include retail medical supplies, bio-cosmetics, health food and other medical-related 
business.
1.2. Event study
An event study is widely applied to determine whether there has been any informa-
tion effect on the stock performance around the announcement date in different events 
(Davidson et al. 1987; Rajiv et al. 1993; Bradford, Robinson 1997; Patten, Nance 1998; 
Pantzalis et al. 2000; Chen, Su 2010; Lai et al. 2010; Ramiah et al. 2010; Chuang, 
Wang 2010; Asgharian et al. 2011; Cheung 2011; Li, Tallman 2011; Ramchander et al. 
2012). Recent literature used event study to measure the effect of specific events, such 
as the effect of the Alaskan oil spill on the stock performance of petroleum companies 
and the effect of war on the stock performance of transportation companies. When the 
business of a company is affected by a specific event, either directly or indirectly, the 
result is significant abnormal returns (Epstein, Schnietz 2002; Chen 2005; Returns et al. 
2007; Lin et al. 2008; Raghu et al. 2008; Chavis, Leslie 2009; Yanase, Yasuda 2010; 
Konchitchki, O’Leary 2011; Castañeda, Vargas 2012; Da Graca, Masson 2012). 
 Event study analysis has been applied to examine the relationship between the outbreak 
of an infectious disease and the stock performance of Taiwan’s biotechnology industry. 
The announcement date for each disease is determined by the day of the first confirmed 
death case in Taiwan. The announcement date for ENTEROVIRUS 71 was May 27, 
1998; for DENGUE FEVER it was July 14, 2002; for SARS it was April 27, 2003; 
and for H1N1 it was July 30, 2009. The event period is 31 trading days. The estimated 
period consists of 90 trading days prior to the event period. The expected return was 
derived using the market model and Ordinary Least Square (OLS), which is based on 
the following regression model:
 .it i i mt itR R= α + β + ε   (1)
When beta is estimated by ordinary least squares, it will result in the risk factor of a 
relatively infrequent stock being underestimated. Where there are relatively frequent 
stock transactions, the risk factor tends to be overestimated (Scholes, Williams 1977). 
The following formula is applied to adjust the risk factor:
 











∗β  is the unbiased estimator beta coefficients of firm I; ˆ i−β  is the estimators of return 
of firm i and previous market return by ordinary least squares; ˆ i+β  is the estimators of 
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return of firm i and latter market return by ordinary least squares; and ˆ mρ  is the autocor-
relation coefficient of market rate of return.
The value of the intercept is estimated by least squares model based on Eq. (3):
 
ˆˆ i i i mR R∗ ∗α = −β ,  (3)
iR  is average return of firm i for the estimated period. mR  is average market rate of 
return.














where t = –15, –14, …, 0, …, 14, 15 ,and N is total observations.
Cumulative abnormal return (CAR) can be calculated as the abnormal return through t 
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Var(CAR(t1, t2)) is the variance of CAR(t1, t2).
2. Empirical results
2.1. The results of all samples
To test whether infectious diseases impact biotechnology stock performance, event 
study analysis is applied to examine the relationship between the date of infectious dis-
ease outbreak and the performance of Taiwanese biotechnology stocks. Table1 presents 
abnormal returns (AR) for biotechnology stocks. The empirical results show that there 
are significantly positive abnormal returns on days –15, –12, –9, –8, –3, 1, 8 and 15. 
They are statistically significant at 0.01 levels on days –15, –12, –9, –8, –3, 1 and 15. 
They are statistically significant at 0.05 levels on day 8.There are significantly negative 
abnormal returns on days –14, –13, –7, –6, – 4, 3, 6, 11, 12 and 14. They are statistically 
significant at 0.01 levels on days –13,–7, –4, 3, 11, 12 and 14. They are statistically 
significant at 0.05 levels on days –6 and 6. They are statistically significant at 0.1 levels 
on day –14. The abnormal return on announcement date (date 0) is not significant.
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Table 1. AR of biotechnology industry during the period of infectious diseases
Event window AR t-test Event window AR t-test
–15 1.7596 5.1959 *** 1 0.9523 3.1052 ***
–14 –0.5131 –1.6825 * 2 –0.4400 –1.4446
–13 –1.9147 –5.5174 *** 3 –2.0381 –4.9559 ***
–12 1.6952 5.6322 *** 4 –0.6215 –1.4511
–11 0.2873 1.0665 5 –0.0591 –0.2147
–10 –0.0871 –0.3006 6 –0.4607 –2.1957 **
–9 1.6739 5.2637 *** 7 –0.0357 –0.1662
–8 0.8678 2.7689 *** 8 0.4114 1.9882 **
–7 –1.6104 –4.7187 *** 9 0.0333 0.1529
–6 –0.5390 –2.1302 ** 10 –0.2722 –1.5304
–5 0.3356 0.9220 11 –1.5548 –7.3989 ***
–4 –0.8910 –3.4128 *** 12 –0.8274 –2.7014 ***
–3 1.0548 3.8269 *** 13 0.0641 0.3437
–2 0.4289 1.0493 14 –0.6959 –2.9054 ***
–1 –0.2551 –0.7978 15 0.8750 2.8993 ***
0 0.0983 0.2858
Notes: * Significant level 0.1; ** Significant level 0.05; *** Significant level 0.01.
Table 2 presents the cumulative abnormal returns (CAR) of biotechnology stocks. The 
empirical evidence found that there are significantly positive cumulative abnormal re-
turns on days –15, –14, –11, –10, –9, –8, –7, –6, –5, –3, –2, –1, 0, 1 and 2 ; there are 
significantly positive cumulative abnormal returns at 0.01 level on days –15, –14, –9, 
–8, 1 and 2. They are statistically significant at 0.05 levels on days –11, –7, –5, –3, –2, 
–1 and 0. They are statistically significant at 0.1 levels on days –10 and –6. There are 
significantly negative cumulative abnormal returns on days 12, 13, 14 and 15. They are 
statistically significant at 0.05 levels on day 14. They are statistically significant at 0.1 
levels on days 12, 13 and 15. Investors think that the outbreak of infectious diseases 
may be favorable to biotechnology stock performance. But when infectious diseases 
continued to spread, biotechnology stock performance steadily worsened.
2.2. Results of classified samples
In order to test the robustness of the results, the Biotechnology industry is divided 
into three major categories: pharmaceuticals, medical products, and other medical-re-
lated products. Table 3 presents abnormal returns for pharmaceutical product stocks. 
Empirical results show that there were significantly positive abnormal returns on days 
–15, –12, –9, –3, 1 and 15. These were statistically significant at 0.01 levels on days 
–15, –12 and –9. They were statistically significant at 0.05 levels on days –3 and 1. 
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Table 2. CAR of biotechnology industry during the period of infectious diseases
Event window CAR t-test Event window CAR t-test
–15 1.7596 5.1959 *** 1 3.3434 2.9723 ***
–14 1.2465 2.9564 *** 2 2.9033 2.7054 ***
–13 –0.6682 –1.2509 3 0.8653 0.8079
–12 1.0270 1.5176 4 0.2438 0.2186
–11 1.3143 2.0185 ** 5 0.1847 0.1694
–10 1.2273 1.6745 * 6 –0.2760 –0.2397
–9 2.9011 3.4242 *** 7 –0.3117 –0.2723
–8 3.7689 4.0817 *** 8 0.0996 0.0891
–7 2.1585 2.4988 ** 9 0.1329 0.1162
–6 1.6195 1.8860 * 10 –0.1392 –0.1195
–5 1.9551 2.2369 ** 11 –1.6941 –1.3750
–4 1.0642 1.1768 12 –2.5214 –1.8580 *
–3 2.1190 2.1256 ** 13 –2.4573 –1.8648 *
–2 2.5479 2.3583 ** 14 –3.1532 –2.1909 **
–1 2.2928 2.1098 ** 15 –2.2781 –1.6501 *
0 2.3911 2.0936 **
Notes: * Significant level 0.1; ** Significant level 0.05; *** Significant level 0.01.
Table 3. Average AR of pharmaceutical during the period of infectious diseases
Event window AR t-test Event window AR t-test
–15 1.7698 3.4963 *** 1 1.1341 2.3622 **
–14 –0.4402 –1.0220 2 –0.8786 –2.0077 **
–13 –1.3783 –2.7689 *** 3 –1.7712 –2.8562 ***
–12 1.7962 4.5583 *** 4 –0.1020 –0.1640
–11 –0.2112 –0.6254 5 0.1082 0.2694
–10 0.1690 0.3816 6 –0.8123 –2.3204 **
–9 1.5672 3.5193 *** 7 –0.1222 –0.3629
–8 0.1374 0.3542 8 0.3371 1.1041
–7 –1.7028 –3.7147 *** 9 0.3516 1.0430
–6 –0.5846 –1.7032 * 10 –0.1911 –0.7391
–5 0.6878 1.1118 11 –1.4844 –4.8909 ***
–4 –0.9685 –2.6611 *** 12 –0.5625 –1.3272
–3 0.9373 2.5027 ** 13 0.0780 0.2757
–2 0.6873 1.0567 14 –0.5745 –1.9166 *
–1 –0.6743 –1.4451 15 0.8094 1.8368 *
0 –0.1855 –0.4234
Notes: * Significant level 0.1; ** Significant level 0.05; *** Significant level 0.01.
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They were statistically significant at 0.1 levels on day 15. There were significantly 
negative abnormal returns on days –13, –7, –6, –4, 2, 3, 6 and 11. They are statistically 
significant at 0.01 levels on days –13,–7, –4, 3 and 11. They are statistically significant 
at 0.05 levels on days 2 and 6. They are statistically significant at 0.1 levels on day –6.
Table 4 presents cumulative abnormal returns for pharmaceutical product stocks. The 
empirical evidence found that there were significantly positive cumulative abnormal 
returns on days –15, –14, –12, –9, –8 and 1. There were significantly positive cumula-
tive abnormal returns at 0.01 levels on days –15. They were statistically significant at 
0.05 levels on days –9 and –8. They were statistically significant at 0.1 levels on days 
–14, –12 and 1. There were significantly negative cumulative abnormal returns on day 
14, and they were statistically significant at 0.1 levels. The pharmaceutical category 
displayed significantly positive cumulative abnormal returns before day 1. There were 
significantly negative cumulative abnormal returns after day 6. This result is consistent 
with the general results of the total observation.
Table 4. CAR of pharmaceutical during the period of infectious diseases
Event window CAR t-test Event window CAR t-test
–15 1.7698 3.4963 *** 1 2.7407 1.6902 *
–14 1.3295 1.9109 * 2 1.8621 1.2716
–13 –0.0488 –0.0606 3 0.0909 0.0634
–12 1.7474 1.6665 * 4 –0.0110 –0.0079
–11 1.5362 1.4792 5 0.0972 0.0736
–10 1.7053 1.4124 6 –0.7151 –0.4736
–9 3.2724 2.5672 ** 7 –0.8373 –0.5689
–8 3.4098 2.4425 ** 8 –0.5002 –0.3668
–7 1.7070 1.3203 9 –0.1486 –0.1116
–6 1.1225 0.8456 10 –0.3397 –0.2425
–5 1.8102 1.3700 11 –1.8242 –1.2408
–4 0.8417 0.6397 12 –2.3867 –1.4408
–3 1.7790 1.2409 13 –2.3087 –1.4227
–2 2.4663 1.5649 14 –2.8832 –1.7383 *
–1 1.7920 1.1060 15 –2.0738 –1.2694
0 1.6065 1.0017
Notes: * Significant level 0.1; ** Significant level 0.05; *** Significant level 0.01.
Table 5 presents the abnormal returns attained by medical product stocks. The empirical 
results show that there were significantly positive abnormal returns on days –15, –12, 
–11, –9, –8, –3 and 15. They were statistically significant at 0.01 levels on days –12, 
–9 and –8. They were statistically significant at 0.05 levels on days –15, –3 and 15. 
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They were statistically significant at 0.1 levels on day –11.There were significantly 
negative abnormal returns on days –13, –7, –4, 3, 4, 11 and 12. They were statistically 
significant at 0.01 levels on days –13, 3 and 11. They were statistically significant at 
0.05 levels on days –7, –4 and 4. They were statistically significant at 0.1 levels on 
day 12.
Table 5. Average AR of medical product during the period of infectious diseases
Event window AR t-test Event window AR t-test
–15 1.3753 2.3978 ** 1 0.8340 1.6053
–14 –0.2483 –0.5005 2 –0.2437 –0.4885
–13 –2.1570 –3.7220 *** 3 –2.4577 –4.0233 ***
–12 1.4749 2.5933 *** 4 –1.4192 –2.1139 **
–11 0.8666 1.8189 * 5 –0.3736 –0.9006
–10 –0.4599 –1.0489 6 0.0124 0.0435
–9 1.6713 2.9825 *** 7 0.1796 0.5347
–8 1.5024 2.6786 *** 8 0.1882 0.7065
–7 –1.2521 –1.9746 ** 9 –0.1582 –0.4860
–6 –0.3920 –0.8265 10 –0.4990 –1.5633
–5 0.2237 0.4329 11 –1.5407 –4.4067 ***
–4 –0.9421 –2.1106 ** 12 –1.0278 –1.9246 *
–3 1.2136 2.5509 ** 13 0.1735 0.5825
–2 0.5887 0.9425 14 –0.7148 –1.5480
–1 0.2610 0.4648 15 1.1316 2.2302 **
0 0.4413 0.6784
Notes: * Significant level 0.1; ** Significant level 0.05; *** Significant level 0.01.
Table 6 presents cumulative abnormal returns of medical product stocks. The empiri-
cal evidence found that there were significantly positive cumulative abnormal returns 
on days –15, –14, –9, –8, –7, –6, –5, –3, –2, –1, 0, 1 and 2. There were significantly 
positive cumulative abnormal returns at 0.01 levels on day –8. They were statistically 
significant at 0.05 levels on days –15, –1, 0, 1 and 2. They were statistically significant 
at 0.1 levels on days –14, –9, –7, –6, –5, –3 and –2. The medical product category 
displayed significantly positive cumulative abnormal returns before day 2. They were 
significant from day –9 to day –5 and day –3 to day 2. The outbreak of an infectious 
disease was favorable to stock performance within the medical product category during 
the event period.
Table 7 presents the abnormal returns of other medical–related product stocks. The 
empirical results show that there were significantly positive abnormal returns on days 
–15, –12, –9, –8, 1 and 8. They were statistically significant at 0.01 levels on days–15, 
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Table 6. CAR of medical product during the period of infectious diseases
Event window CAR t-test Event window CAR t-test
–15 1.3753 2.3978 ** 1 5.0011 2.5368 **
–14 1.1270 1.8226 * 2 4.7575 2.4022 **
–13 –1.0300 –1.1807 3 2.2997 1.1354
–12 0.4450 0.4153 4 0.8805 0.4066
–11 1.3115 1.2897 5 0.5069 0.2301
–10 0.8516 0.7639 6 0.5193 0.2342
–9 2.5229 1.7332 * 7 0.6989 0.3198
–8 4.0253 2.5955 *** 8 0.8871 0.4057
–7 2.7731 1.8761 * 9 0.7289 0.3200
–6 2.3811 1.6889 * 10 0.2300 0.1006
–5 2.6048 1.7805 * 11 –1.3107 –0.5268
–4 1.6627 1.0569 12 –2.3385 –0.8729
–3 2.8763 1.6630 * 13 –2.1651 –0.8329
–2 3.4649 1.8529 * 14 –2.8798 –0.9799
–1 3.7259 2.0152 ** 15 –1.7483 –0.6238
0 4.1672 2.0251 **
Notes: * Significant level 0.1; ** Significant level 0.05; *** Significant level 0.01.
Table 7. Average AR of other medical–related during the period of infectious diseases
Event window AR t-test Event window AR t-test
–15 2.8373 4.8648 *** 1 0.6405 1.9436 *
–14 –1.5431 –1.7547 * 2 0.5695 0.7398
–13 –3.1430 –3.9739 *** 3 –1.7820 –1.4150
–12 1.9703 2.8860 *** 4 –0.1781 –0.1455
–11 0.4023 0.5094 5 0.2505 0.2785
–10 0.0722 0.0920 6 –0.5671 –1.5133
–9 2.0654 2.6550 *** 7 –0.3489 –0.7546
–8 1.6567 1.9809 ** 8 1.3259 1.7361 *
–7 –2.3164 –3.2363 *** 9 –0.5574 –1.0466
–6 –0.8015 –1.5895 10 0.0939 0.3803
–5 –0.6075 –1.2075 11 –1.8492 –3.2740 ***
–4 –0.4635 –0.6384 12 –1.1995 –1.4993
–3 1.0176 1.2473 13 –0.3029 –0.6669
–2 –0.9644 –1.2322 14 –1.0783 –1.8651 *
–1 –0.2427 –0.4787 15 0.3677 0.5075
0 0.1252 0.1478
Notes: * Significant level 0.1; ** Significant level 0.05; *** Significant level 0.01.
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–12 and –9. They were statistically significant at 0.05 levels on day –8. They were 
statistically significant at 0.1 levels on days 1 and 8. There were significantly negative 
abnormal returns on days –14, –13, –7, 11 and 14. They were statistically significant 
at 0.01 levels on days –13, –7 and 11. They were statistically significant at 0.1 levels 
on days –14 and 14.
Table 8 presents the cumulative abnormal returns of other medical–related stocks. The 
empirical evidence found that there were significantly positive cumulative abnormal 
returns on days –15, –9 and –8. There were significantly positive cumulative abnormal 
returns at 0.01 levels on day –15. They were statistically significant at 0.05 levels on 
day –8. They were statistically significant at 0.1 levels on day –9. The “other medical-
related” category had only significantly positive cumulative abnormal returns. In sum-
mary, the outbreak of infectious diseases was favorable to stock performance in the 
“other medical–related” category during the event period. Overall, the results of the 
pharmaceutical product category displayed significantly positive cumulative abnormal 
returns before day 1 and significantly negative cumulative abnormal returns after day 6. 
The other two categories had only significantly positive cumulative abnormal returns. 
Table 8. CAR of other medical–related during the period of infectious diseases
Event window CAR t-test Event window CAR t-test
–15 2.8373 4.8648 *** 1 0.7055 0.3385
–14 1.2942 1.5164 2 1.2750 0.6558
–13 –1.8489 –1.6068 3 –0.5070 –0.2606
–12 0.1214 0.0841 4 –0.6850 –0.2648
–11 0.5237 0.4107 5 –0.4345 –0.1936
–10 0.5960 0.5184 6 –1.0016 –0.4420
–9 2.6614 1.7576 * 7 –1.3505 –0.5169
–8 4.3182 2.3123 ** 8 –0.0246 –0.0089
–7 2.0018 1.2185 9 –0.5820 –0.1950
–6 1.2003 0.7497 10 –0.4881 –0.1626
–5 0.5928 0.3418 11 –2.3373 –0.8603
–4 0.1293 0.0679 12 –3.5368 –1.1043
–3 1.1469 0.5036 13 –3.8397 –1.2797
–2 0.1825 0.0836 14 –4.9180 –1.4901
–1 –0.0602 –0.0307 15 –4.5504 –1.5485
0 0.0649 0.0311
Notes: * Significant level 0.1; ** Significant level 0.05; *** Significant level 0.01.
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2.3. Windows analysis and cross-sectional regression analyses
As shown by the results described in the previous paragraphs, infectious diseases affect 
stock performance both positively and negatively. As we seek to further narrow the 
window of analysis, Table 9 presents cumulative abnormal returns separately over the 
event periods; the CAR over the event windows (–10, 10), (–9, 9), (–8, 8), (–7, 7), (–6, 
6), (–5, 5), (–4, 4), (–3, 3), (–2, 2) and (–1, 1) are calculated. There are significantly 
negative cumulative abnormal returns of the period (–8, 8), (–7, 7), (–6, 6) and (–4, 4). 
Although stock performance within the biotechnology industry shows both significantly 
positive and negative cumulative abnormal returns within an event period, it was found 
there is a significantly negative cumulative abnormal return within 2 weeks of the an-
nouncement date such as period (–8, 8), (–7, 7), (–6, 6) and (–4, 4).
Table 9. Windows analysis of CAR
Interval CAR t-test
–10 to 10 –1.4535 –1.1078
–9 to 9 –1.0943 –0.8839
–8 to 8 –2.8014 –2.1433 **
–7 to 7 –4.0806 –3.0499 ***
–6 to 6 –2.4345 –2.1840 **
–5 to 5 –1.4348 –1.4382
–4 to 4 –1.7113 –1.9626 **
–3 to 3 –0.1988 1.6657
–2 to 2 0.7843 1.2189
–1 to 1 0.7954 1.1369
Notes: * Significant level 0.1; ** Significant level 0.05; *** Significant level 0.01.
The abnormal returns were further analyzed according to the financial ratios of biotech 
companies. Gross profit margins, research and development expense ratios, current ra-
tios and the firm scale were applied for factor analysis. Financial ratios of the company 
are from the financial statements of the year prior to the announcement date. The firm 
scale is estimated by the book value of assets. The assets data are changed into a natu-
ral logarithm. Table 10 presents a cross-sectional regression analysis of event windows 
(–7, 7) which often brings abnormal returns to biotechnology industries. Because event 
windows (–7, 7) are the most significant, they were chosen as the independent variable. 
The biotechnology industry share price responses were significantly affected by the re-
search and development expense ratio, as well as current ratio and assets. The research 
and development expense ratio was significantly negative at 0.01 levels. Current ratio 
and assets are significantly positive at 0.1 levels. 
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The higher research and development (R&D) expense ratio for companies resulted in a 
negative effect. Investors care about the companies’ long–term interests and the success 
of development will result in receiving substantial long–term benefits. Investors were 
more confident with companies with a higher R&D expense ratio because they seemed 
to face a better future. The failure of R&D results in adverse consequences once again 
proved the importance of R&D to biotechnology.
The higher current ratio of companies achieved the enhanced effect by the outbreak of 
infectious diseases. The higher current ratio represents better solvency in the short–term. 
However, biotechnology is a capital intensive industry and the biotechnology companies 
having higher current ratios achieve higher abnormal returns.
 The higher assets of companies were achieved by the outbreak of infectious diseases 
and the larger companies experienced the greatest effect. Investors displayed less con-
fidence in those companies when infectious diseases were actually spreading. Because 
large companies have larger scale, their resources can be controlled efficiently in an 
emergency environment. 
Table 10. Cross-sectional regression analyses of factors affecting CAR
Variable Coefficient
Constant –47.8592**
Gross profit margin 0.1623
R &D expense ratio  –1.4574***





Notes: * Significant level 0.1; ** Significant level 0.05; *** Significant level 0.01.
Conclusions
The development of the biotechnology industry has been vigorous in Taiwan during 
recent years. This paper investigated the outbreak of infectious diseases and how such 
events affect the stock performance of biotechnology companies. Observations were 
based upon the stock performance of thirty-eight listed Taiwanese companies. Observed 
events of major infectious disease outbreaks in the past ten years in Taiwan, included 
ENTEROVIRUS 71, DENGUE FEVER, SARS and H1N1. 
The results show that the outbreak of infectious diseases significantly affects biotechnol-
ogy stock performance. There were significantly positive cumulative abnormal returns 
before day 2. There were significantly negative cumulative abnormal returns after day 
12. According to Yang et al. (2010), the results showed significantly positive cumula-
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tive abnormal returns before day 2, but there were no significantly negative cumulative 
abnormal returns. The results of this paper are consistent with those of Yang et al. 
(2010) before day 2, but differ after day 2 since stock price indicates significantly 
positive cumulative abnormal returns before day 2. In other words, investors think that 
the outbreak of infectious diseases is favorable to the stock performance of biotechnol-
ogy companies. However, when infectious diseases appeared to be spreading, biotech-
nology stock performance worsened; this indicates that the event (the first confirmed 
death case) may change the judgments of investors and may explain why there were 
no significantly positive cumulative abnormal returns after day 2; significantly negative 
cumulative abnormal returns may even result. 
The pharmaceutical category showed significantly positive cumulative abnormal re-
turns before day 1 and significantly negative cumulative abnormal returns after day 6. 
The other two categories only had significantly positive cumulative abnormal returns. 
When infectious diseases were continuously spreading, demand for medical products 
and consumables increased and investors expected those companies’ operating revenues 
to increase significantly. In other words, the outbreak of infectious diseases was fa-
vorable to the stock performance of companies producing medical products and other 
medical-related products during the event period. It was not clear whether or not the 
outbreak of infectious diseases was favorable to stock performance of pharmaceutical 
category. Hence, when infectious diseases are continuously spreading, investors may 
consider the risk of holding stocks as too high and begin selling shares; stock prices 
began to adjust downward after day 4.
Finally we further narrowed the window of analysis. We found significantly negative 
cumulative abnormal returns within 2 weeks of the announcement date. In addition, we 
analyzed the abnormal returns by financial ratios of biotechnology companies. The re-
sults indicate that a higher R&D expense ratio for companies produced a negative effect 
as the result of an outbreak of an infectious disease. Higher current ratio and assets of 
companies resulted from the outbreak of infectious diseases. This information may be 
important for biotechnology management; if in the future top management encounters 
the same situation, they should sustain the confidence level of investors by reducing the 
uncertainty of stocks in the market.
Most of Taiwanese biotechnology industries are medium-sized enterprises, and their 
operating ability and capital turnover are usually not as good as the stability of large-
sized enterprises. Therefore, how to use the excess stock returns and financial statements 
information is an important part of risk prevention. From an investor’s perspective, the 
results of this study reflect not only the operating conditions of the company, but also 
to reduce investment risks brought about by the investing information asymmetry.
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